- US clinical-stage biopharmaceutical company Zentalis Pharmaceuticals (NASDAQ:ZNTL) has commenced a $150M underwritten public offering of common shares.
- All common shares issued in the offering will be sold by Zentalis. A 30-day option will be granted to underwriters to purchase up to $22.5M in additional stock.
- Earlier today, Zentalis Pharmaceuticals shares slid after its experimental cancer therapeutic ZN-c5 indicated a mixed performance in early-stage data.
Zentalis Pharmaceuticals commences proposed public stock offering
Recommended For You
More Trending News
About ZNTL Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ZNTL | - | - |
Zentalis Pharmaceuticals, Inc. |